Analysts Set Repligen Co. (NASDAQ:RGEN) Target Price at $301.50

Shares of Repligen Co. (NASDAQ:RGEN – Get Rating) have received an average recommendation of “Moderate Buy” from the seven research firms that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $301.50.

A number of equities research analysts have issued reports on the company. Craig Hallum lowered their price target on Repligen from $286.00 to $274.00 in a research report on Thursday, April 28th. StockNews.com began coverage on Repligen in a research note on Thursday, March 31st. They set a “hold” rating on the stock.

RGEN stock opened at $148.71 on Thursday. The stock has a 50-day moving average price of $154.74 and a two-hundred day moving average price of $186.68. Repligen has a 12-month low of $137.21 and a 12-month high of $327.32. The company has a market cap of $8.09 billion, a PE ratio of 58.78 and a beta of 0.98.

Repligen (NASDAQ:RGEN – Get Rating) last posted its quarterly earnings results on Wednesday, April 27th. The biotechnology company reported $0.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.72 by $0.20. Repligen had a return on equity of 11.13% and a net margin of 19.86%. The firm had revenue of $206.40 million during the quarter, compared to the consensus estimate of $185.48 million. During the same quarter in the previous year, the business earned $0.68 earnings per share. The firm’s quarterly revenue was up 44.5% compared to the same quarter last year. Equities analysts predict that Repligen will post 3.1 earnings per share for the current fiscal year.

In related news, Director Karen A. Dawes sold 14,715 shares of the business’s stock in a transaction dated Wednesday, May 25th. The stock was sold at an average price of $150.51, for a total value of $2,214,754.65. Following the transaction, the director now owns 76,532 shares in the company, valued at $11,518,831.32. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 1.10% of the company’s stock.

Several large investors have recently bought and sold shares of the company. Walleye Capital LLC bought a new position in shares of Repligen during the first quarter valued at approximately $434,000. Advisory Services Network LLC grew its holdings in shares of Repligen by 4.9% during the first quarter. Advisory Services Network LLC now owns 3,463 shares of the biotechnology company’s stock valued at $651,000 after purchasing an additional 162 shares during the last quarter. Toroso Investments LLC grew its holdings in shares of Repligen by 15.3% during the first quarter. Toroso Investments LLC now owns 1,079 shares of the biotechnology company’s stock valued at $203,000 after purchasing an additional 143 shares during the last quarter. Alyeska Investment Group L.P. bought a new position in shares of Repligen during the first quarter valued at approximately $3,681,000. Finally, Eaton Vance Management grew its holdings in shares of Repligen by 9.0% during the first quarter. Eaton Vance Management now owns 144,824 shares of the biotechnology company’s stock valued at $27,239,000 after purchasing an additional 11,992 shares during the last quarter. 86.82% of the stock is owned by institutional investors.

About Repligen (Get Rating)

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

Featured Stories